STUDY OBJECTIVES Esmirtazapine (1.5-4.5 mg) has demonstrated short-term sleep-promoting effects in non-elderly outpatients with chronic insomnia. This Phase 3, randomized, double-blind study (NCT00631657) and its open-label extension (NCT00750919) investigated efficacy and safety of long-term esmirtazapine treatment in adult outpatients with chronic insomnia. METHODS Participants were randomized to receive esmirtazapine 4.5 mg or placebo for 6 months; those receiving esmirtazapine were then re-randomized to esmirtazapine or placebo for an additional 7 days. Participants could enter the 6-month open-label extension with esmirtazapine 4.5 mg. The primary objective of the double-blind study was to assess long-term efficacy of esmirtazapine versus placebo on self-reported total sleep time. Assessing long-term safety and tolerability were secondary and primary objectives of the double-blind and extension studies, respectively. RESULTS Overall, 457 participants received treatment in the double-blind study (esmirtaz57; https//clinicaltrials.gov/ct2/show/NCT00631657) and "Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)" (NCT00750919; https//clinicaltrials.gov/ct2/show/NCT00750919). © 2020 American Academy of Sleep Medicine.INTRODUCTION In recent years, increased awareness and focus on chronic obstructive pulmonary disease (COPD) has evolved. Alongside, a growing interest has emerged in quality of care including early diagnosis, smoking cessation, rehabilitation and relevant medication as tools for achieving a better prognosis. METHODS The aim of this study was to analyse the quality of real-life management of COPD in a representative sample of Danish general practices. Our main focus was to measure the fulfilment of ten specific quality-of-care indicators at the annual control visit for management of COPD, as suggested by the Danish Society of General Practitioners (DSAM), by extracting relevant data from the electronic patient medical records (PMR) of the general practitioners' (GP) electronic patient filing systems. RESULTS In total, 82 GP clinics participated in the study. Approximately half were solo clinics and the rest were various types of partnership clinics. The records of 1,556 COPD patients (51.3% males) with an averhe original author(s) and source are credited.INTRODUCTION Transfusion of blood products occurs frequently as part of the treatment of post-partum haemorrhage, but since it is both expensive and has potentially severe complications, prescription of blood products should be restricted. The aim of this study was to examine if restrictive red blood cell transfusion (RBC-T) practice for obstetric patients was in line with national Danish guidelines. METHODS A retrospective quality assurance study was conducted at Rigshospitalet, Denmark. The study counted the participation of the Department of Anaesthesiology and Surgery, the Juliane Marie Centre, the Danish Blood Bank and the Department of Obstetrics. Patients were identified via the patient database of the Danish Blood Bank in 2015-2017, and patient files were read. RESULTS Out of 16,698 delivering women, 196 (1.2%) received one or more RBC-T from 2015 to 2017. A total of 133 women (67.9%) received more than one RBC-T and the median was two. The most common reason for RBC-T was a "low haemoglobin level (Hb) + anaemic symptoms" (37.0%). A total of 20.3% of all RBC-Ts were prescribed based simply on a low Hb. The most common symptom of anaemia was dizziness. CONCLUSIONS The majority of RBC-Ts for obstetric patients were conducted in line with the guidelines. However, 6.0% of RBC-Ts were registered to be in discrepancy with the guidelines and 20.3% of RBC-Ts were prescribed on the "low Hb" criterium solely. It is possible, though, that the 20.3% is overestimated due to insufficient descriptions of indications for RBC-T in patient files. FUNDING none. TRIAL REGISTRATION The study was approved by the management at Rigshospitalet. Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.INTRODUCTION Hypoparathyroidism (HypoPT) is the most common complication after total thyroidectomy (TT). Recent literature report incidences of HypoPT that are higher than previously anticipated. This study aimed to assess the incidence of transient and chronic HypoPT in patients undergoing TT and to specify risk factors and recovery time. METHODS This was a retrospective review of patients undergoing TT in the period from 2013 to 2018 due to benign thyroid disease in a Danish university hospital. In total, 187 patients were eligible for inclusion.  https://www.selleckchem.com/products/bpv-hopic.html  Data were collected from internal medical files, the Thykir database sheets and patient records. HypoPT was defined as SE-ionised-Ca2+ levels (Less than 1.16 mmol/l) and inappropriately low parathyroid hormone levels. RESULTS The incidence of transient and chronic HypoPT was 81 (43.3%) and 25 (13.4%), respectively. Younger ages and toxic indication for surgery were independent risk factors for transient and chronic HypoPT. Incidences in Graves' disease population were 70.5% and 27.3%, respectively. Resolution within the first months was seen in 48.2% of the patients with acute transient HypoPT. CONCLUSIONS The incidence of chronic HypoPT after TT is higher than previously reported. This is primarily due to a lack of consistency in the definition and follow-up time between studies. Younger patients and those with a toxic indication for surgery are at higher risk of HypoPT after TT than other patients. FUNDING none. TRIAL REGISTRATION The study was approved by the Danish Data Protection Agency (REG-015-2019) and The Ethical Committee of Central Denmark (No. 66792). Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.